Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vorinostat Velcade Dexamethasone · 1 trial · 1 indication
To assess the number and proportion of participants with at least a partial response (PR) or better within 8 cycles of protocol treatment with vorinostat, bortezomib and dexamethasone.
| Arm | Type | Description |
|---|---|---|
| Vorinostat Velcade Dexamethasone (VVD) | EXPERIMENTAL | Up to 8 cycles of VVD followed by vorinostat maintenance until disease progression. Cycles 1-8 (21-day cycle) * Velcade: 1.3mg/m2 (subcutaneous) on days 1, 4, 8 and 11 * Dexamethasone: 20 mg (PO) on days 1, 2, 4, 5, 8, 9, 11 and 12 * Vorinostat: 400mg (PO) on days 1-4, 8-11, 15-18 Maintenance (28-day cycle) * Vorinostat: 400mg PO on 1-4 and 15-18 |
| Name | Type | Description |
|---|---|---|
| Vorinostat Velcade Dexamethasone | DRUG | - |
Inclusion Criteria: * Able to give informed consent - Aged 18 years or over * Participants with relapsed myeloma who have received 1-3 prior lines of treatment and now require further treatment * ECOG Performance Status ≤ 2 * Required laboratory values within 14 days of registration: * Absolute ...
Top 20 of 25 competitors
Vorinostat Velcade Dexamethasone is an investigational combination therapy being studied for the treatment of multiple myeloma, a cancer of plasma cells. It combines vorinostat, bortezomib (Velcade), and dexamethasone. The combination is currently in clinical development and is not approved for use.
Vorinostat Velcade Dexamethasone is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate this combination therapy for multiple myeloma.
Vorinostat Velcade Dexamethasone is in Phase 2 clinical development. It is an investigational combination therapy for multiple myeloma and has not been approved by regulatory authorities. The Phase 2 trial has been completed.
Vorinostat Velcade Dexamethasone was studied in a Phase 2 clinical trial with the identifier NCT01720875, titled 'Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)'. This trial, conducted in the United Kingdom, enrolled 16 participants and has been completed.
Yes, Vorinostat Velcade Dexamethasone refers to a combination of three drugs: vorinostat, bortezomib (also known as Velcade), and dexamethasone. This combination is being investigated for the treatment of multiple myeloma in a Phase 2 clinical trial.